DD201447A5 - Verfahren zur herstellung von als antikrebsmittel wirksamen immunoglobulin-konjugaten - Google Patents

Verfahren zur herstellung von als antikrebsmittel wirksamen immunoglobulin-konjugaten Download PDF

Info

Publication number
DD201447A5
DD201447A5 DD82236636A DD23663682A DD201447A5 DD 201447 A5 DD201447 A5 DD 201447A5 DD 82236636 A DD82236636 A DD 82236636A DD 23663682 A DD23663682 A DD 23663682A DD 201447 A5 DD201447 A5 DD 201447A5
Authority
DD
German Democratic Republic
Prior art keywords
immunoglobulin
conjugate
preparation
cells
vindesine
Prior art date
Application number
DD82236636A
Other languages
German (de)
English (en)
Inventor
George F Rowland
Robin G Simmonds
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd
Publication of DD201447A5 publication Critical patent/DD201447A5/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6805Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a vinca alkaloid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DD82236636A 1981-01-12 1982-01-08 Verfahren zur herstellung von als antikrebsmittel wirksamen immunoglobulin-konjugaten DD201447A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8100847 1981-01-12

Publications (1)

Publication Number Publication Date
DD201447A5 true DD201447A5 (de) 1983-07-20

Family

ID=10518931

Family Applications (1)

Application Number Title Priority Date Filing Date
DD82236636A DD201447A5 (de) 1981-01-12 1982-01-08 Verfahren zur herstellung von als antikrebsmittel wirksamen immunoglobulin-konjugaten

Country Status (27)

Country Link
EP (1) EP0056322B1 (ru)
JP (1) JPS57136529A (ru)
KR (1) KR860001149B1 (ru)
AT (1) ATE16603T1 (ru)
AU (1) AU549495B2 (ru)
BG (1) BG40318A3 (ru)
CA (1) CA1180660A (ru)
CS (1) CS235525B2 (ru)
DD (1) DD201447A5 (ru)
DE (1) DE3267474D1 (ru)
DK (1) DK5982A (ru)
EG (1) EG15599A (ru)
ES (1) ES508633A0 (ru)
FI (1) FI820020L (ru)
GB (1) GB2090837B (ru)
GR (1) GR75182B (ru)
HU (1) HU186025B (ru)
IE (1) IE52239B1 (ru)
IL (1) IL64722A (ru)
MX (1) MX7215E (ru)
NZ (1) NZ199421A (ru)
PH (1) PH18031A (ru)
PL (1) PL128529B1 (ru)
PT (1) PT74252B (ru)
RO (1) RO82758B (ru)
SU (1) SU1069628A3 (ru)
ZA (1) ZA82122B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639456A (en) * 1980-06-10 1987-01-27 Omnichem S.A. Vinblastin-23-oyl amino acid derivatives
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
ATE57187T1 (de) * 1983-03-30 1990-10-15 Lilly Industries Ltd Vincaleukoblastin-derivate.
GR79899B (ru) * 1983-03-30 1984-10-31 Lilly Industries Ltd
HUT34212A (en) * 1983-04-29 1985-02-28 Omnichem Sa Process for the production of new vindblastin conjugates
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4675400A (en) * 1985-06-17 1987-06-23 Eli Lilly And Company Bifunctional derivatives of 4-desacetyl indole-dihydroindole alkaloids
US4667030A (en) * 1985-06-17 1987-05-19 Eli Lilly And Company Hydrazide succinimide derivatives of antineoplastic indole-dihydroindole alkaloids
FI860456A (fi) * 1985-07-16 1987-01-17 Huhtamaeki Oy Laeaeketehdas Le Bis-indolalkaloiders proteinkonjugat, bis-indolalkaloider, deras framstaellning och anvaendning.
EP0232693A3 (fr) * 1985-12-16 1988-04-06 La Region Wallonne Conjugués de la vinblastine et de ses dérivés, procédé pour leur préparation et compositions pharmaceutiques les contenant
US4801688A (en) * 1986-05-27 1989-01-31 Eli Lilly And Company Hydrazone immunoglobulin conjugates
IL82579A0 (en) * 1986-05-27 1987-11-30 Lilly Co Eli Immunoglobulin conjugates
FR2626882B1 (fr) * 1988-02-08 1991-11-08 Ire Celltarg Sa Conjugues de derives de vinca comportant une chaine detergente en position c-3
US5094849A (en) * 1988-08-08 1992-03-10 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized vinca analogs via simple organic linkers
US5144012A (en) * 1988-08-08 1992-09-01 Eli Lilly And Company Cytotoxic drug conjugates
US5006652A (en) * 1988-08-08 1991-04-09 Eli Lilly And Company Intermediates for antibody-vinca drug conjugates
US5028697A (en) * 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US5043340A (en) * 1990-04-03 1991-08-27 Eli Lilly And Company Derivatives of 4-desacetyl VLB C-3 carboxhydrazide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2456224A1 (de) * 1974-11-28 1976-08-12 Karl Dr Med Theurer Verwendung von nativen antikoerpern oder von antikoerper-fragmenten mit kovalent gebundenen oder konjugierten zytostatisch und/bzw. oder zytotoxisch wirkenden substanzen fuer die krebstherapie
GB1446536A (en) * 1975-02-21 1976-08-18 Yeda Res & Dev Pharmaceutically active compositions
FR2349335A1 (fr) * 1976-04-28 1977-11-25 Inst Int Pathologie Cellulaire Complexes d'alcaloides bis-indoliques du type vinblastine avec la tubuline, leur procede d'obtention et leur utilisation
JPS5470384A (en) * 1977-08-22 1979-06-06 Inst Obu Kiyansaa Risaachi Roi High molecular complex
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
JPS55136235A (en) * 1979-04-09 1980-10-23 Teijin Ltd Antitumor protein complex and its preparation

Also Published As

Publication number Publication date
EP0056322B1 (en) 1985-11-21
GB2090837B (en) 1984-07-18
IL64722A (en) 1985-07-31
SU1069628A3 (ru) 1984-01-23
IE820023L (en) 1982-07-12
PT74252A (en) 1982-02-01
FI820020L (fi) 1982-07-13
DK5982A (da) 1982-07-13
CS235525B2 (en) 1985-05-15
RO82758B (ro) 1984-01-30
ZA82122B (en) 1983-07-27
IE52239B1 (en) 1987-08-19
CA1180660A (en) 1985-01-08
ES8304149A1 (es) 1983-02-16
PL128529B1 (en) 1984-02-29
IL64722A0 (en) 1982-03-31
GR75182B (ru) 1984-07-13
PL234695A1 (ru) 1982-07-19
DE3267474D1 (en) 1986-01-02
MX7215E (es) 1988-01-08
RO82758A (ro) 1984-01-14
BG40318A3 (en) 1986-11-14
AU7927482A (en) 1982-07-22
ES508633A0 (es) 1983-02-16
NZ199421A (en) 1984-08-24
AU549495B2 (en) 1986-01-30
GB2090837A (en) 1982-07-21
PT74252B (en) 1983-08-24
ATE16603T1 (de) 1985-12-15
KR830008684A (ko) 1983-12-12
HU186025B (en) 1985-05-28
EG15599A (en) 1986-06-30
JPS57136529A (en) 1982-08-23
PH18031A (en) 1985-03-06
EP0056322A1 (en) 1982-07-21
KR860001149B1 (ko) 1986-08-18

Similar Documents

Publication Publication Date Title
DD201447A5 (de) Verfahren zur herstellung von als antikrebsmittel wirksamen immunoglobulin-konjugaten
DE69333800T2 (de) Thioether enthaltende Konjugate
DE69838953T2 (de) Methoden zur herstellung von glykosylierten antikörpern und antikörperfragmenten mit reaktiven ketongruppen
DE69636015T2 (de) Bispezifische antikörper in denen die bindungsfähigkeit durch eine mittels licht spaltbare gruppe reversibel inhibiert wird
EP0404097B1 (de) Bispezifische und oligospezifische, mono- und oligovalente Rezeptoren, ihre Herstellung und Verwendung
EP1447099B1 (de) Antineoplastisch wirkende Polyethylenkonjugate zytostatischer Verbindungen und diese enthaltende Arzneimittel
AT394577B (de) Polydom, verfahren zu seiner herstellung und immunodiagnostische verfahren
DE69937899T2 (de) Antikörper-serumprotein hybride
DD204849A5 (de) Verfahren zur herstellung von produkten fuer die behandlung von melanomen
DE2910998A1 (de) Verfahren zur herstellung von gebundenes enzym enthaltenden produkten und deren verwendung
DD209578A5 (de) Verfahren zur herstellung von immunoenzymatischen konjugaten
DE2623736A1 (de) Antitumormittel und verfahren zu dessen herstellung
DE2939165A1 (de) Cytotoxische produkte und verfahren zu ihrer herstellung
DE2507901C2 (ru)
DE69034087T2 (de) Antiidiotypischer Antikörper, der ein Immunantwort gegen ein Glykosphingolipid induziert und seine Verwendung
DE3629194A1 (de) Biotinylierungsreagentien
DE3224217A1 (de) Enzymimmunoassay-methode zur qualitativen und quantitativen bestimmung von substanzen
US4814438A (en) Immunoglobulin conjugates of 2',2'-difluronucleosides
DE3808166C2 (de) Immunglobulinkonjugate, Verfahren zu deren Herstellung sowie pharmazeutische Mittel, die diese enthalten
DE3738721A1 (de) Immobilisierte antikoerper
DE4033714C2 (ru)
EP0403960A2 (de) Magnetische Protein-Konjugate, Verfahren zu ihrer Herstellung und ihre Verwendung
NZ212118A (en) Conjugate of macromolecule and ionophore; use as immunotoxin potentiator
AT393125B (de) Cytorhodin s-derivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
Derbyshire et al. Monoclonal antibodies recognising the cluster 2 antigen associated with human small cell lung cancer mediate the toxic effects of ricin A chain in an indirect assay of immunotoxin cytotoxicity.